ArriVent BioPharma, Inc. AVBP Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s operating lease right-of-use assets in other assets?
- ArriVent BioPharma, Inc. (AVBP) reported operating lease right-of-use assets in other assets of $370K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
- ArriVent BioPharma, Inc.'s operating lease right-of-use assets in other assets increased by 208.3% year-over-year, from $120K to $370K.
- What is the long-term trend for ArriVent BioPharma, Inc.'s operating lease right-of-use assets in other assets?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s operating lease right-of-use assets in other assets has grown at a -78.9% compound annual growth rate (CAGR), from $291K to $13K.